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2767with the LDL-lowering effect, but that this relation-
ship is driven by the total daily dose of nuts, rather
than by differences in phytosterol content between
types of nuts.*Liana C. Del Gobbo, PhD
Michael C. Falk, PhD
Robin Feldman, MBA
Kara Lewis, PhD
Dariush Mozaffarian, MD, DrPH
*Friedman School of Nutrition Science and Policy
Tufts University
150 Harrison Avenue
Boston, Massachusetts 02111
E-mail: Liana.Del_Gobbo@tufts.edu
http://dx.doi.org/10.1016/j.jacc.2015.03.595
Please note: This work was supported by R01-HL085710-07. Drs. Del Gobbo and
Mozaffarian have received modest ad hoc consulting fees from the Life Sciences
Research Organization (LSRO) to support this study. Dr. Mozaffarian has
received ad hoc honoraria from Bunge, Pollock Institute, and Quaker Oats; ad
hoc consulting for Foodminds, Nutrition Impact, Amarin, AstraZeneca, and
Winston and Strawn LLP; has membership in the Unilever North America
Scientiﬁc Advisory Board; and chapter royalties from UpToDate. Drs. Falk,
Feldman, and Lewis received payment through LSRO (<5% of gross income) to
conduct a review of nuts and cardiovascular health outcomes, which was fun-
ded through a contract with the International Tree Nut Council (ITNC). No
author has stock or ownership in the INTC. Funding agencies had no role in the
study design, data collection and analysis, decision to publish, or preparation of
this paper.
RE F E RENCE S
1. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardio-
vascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279–90.
2. Phung OJ, Makanji SS, White CM, et al. Almonds have a neutral effect on
serum lipid proﬁles: a meta-analysis of randomized trials. J Am Diet Assoc
2009;109:865–73.
3. Banel DK, Hu FB. Effects of walnut consumption on blood lipids and other
cardiovascular risk factors: a meta-analysis and systematic review. Am J Clin
Nutr 2009;90:56–63.
4. Phillips KM, Ruggio DM, Ashraf-Khorassani M. Phytosterol composition of
nuts and seeds commonly consumed in the United States. J Agr Food Chem
2005;53:9436–45.When to Call It Severe
Mitral Regurgitation?I read with great interest the article by Grayburn et al.
(1), which deﬁned “severe” secondary mitral regur-
gitation (MR). The investigators did a great job of
explaining the mechanism and application of new
guidelines in the evaluation of MR. The investi-
gators proposed that classiﬁcation of a patient with
severe secondary MR should be deferred until
guideline-directed medical therapy or interventions
are optimized.
Current guidelines for valvular heart disease deﬁne
the class of valvular heart disease by echocardio-
graphic data and symptoms, asymptomatic severe MR(stage C), and symptomatic severe MR (stage D) (2).
However, the severity of MR is primarily based on
the echocardiographic ﬁndings, including color
Doppler, vena contracta, effective regurgitant oriﬁce,
and regurgitant volume and/or fraction. It is well
known that the severity of MR is dependent on the
loading conditions (blood pressure and heart rate),
and that there may be disparities among various pa-
rameters for the assessment of severity. The echo-
cardiologist reading the study may not have any
knowledge about the optimization of the medical
therapy, and may ﬁnd it difﬁcult not to describe a
patient with severe MR if the patient meets the
echocardiographic diagnostic criteria for severe MR.
It seems more logical to say that the decision to
recommend surgical or other invasive procedures
should be deferred until the guideline-directed ther-
apy has been optimized and the severity of MR sub-
sequently reassessed. However, more research is
needed in this area to further deﬁne the duration of
optimal therapy.*Gyanendra K. Sharma, MD
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Mitral Regurgitation?As stated in our review article, functional mitral
regurgitation (MR) is notoriously dynamic and may
change in severity depending on loading conditions
(1). Dr. Sharma correctly points out that echocardi-
ographers may be unaware of whether a given patient
is appropriately treated or not, and therefore, they
must base severity on the echocardiographic ﬁndings
alone. We agree with Dr. Sharma that “the decision to
recommend surgical or other invasive procedures
should be deferred until the guideline-directed
